Vor Bio Announces Research On Barriers To Cell And Gene Therapy Clinical Trial Enrollment, Citing Complexity, Logistical Challenges, And Resource Constraints; Findings Presented At TANDEM Meetings Highlight Need For Improved Patient Experience.

-8.26%

Vor Biopharma, Inc.

VOR

0.00

Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trials
Despite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options

CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials. The data, which was presented at the TANDEM Meetings of ASTCT and CIBMTR, demonstrated the need to improve the process and experience of patients considering and enrolling in CGT trials.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Breakthrough And Pullback | 6 Stocks Deserve Close Attention: NET, OSIS And More

Bernstein Maintains Market Perform on Biogen, Raises Price Target to $157

NewGen Announces Term Sheet For Proposed Reverse Merger With SAXA, Pursuant to Which NewGen Would Issue 550M Shares At $10/Share; Transaction Expected to Provide Co. With Access To SAXA's Portfolio Of Mining Assets Originally Valued At $11B

Oppenheimer Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $250

We're Keeping An Eye On Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Rate

What Natera (NTRA)'s New Clinical Milestones and Expanded Prenatal Testing Mean for Shareholders

How FDA’s Revised Stance on AMT-130 Data Has Changed uniQure’s (QURE) Investment Story

Assessing Intellia Therapeutics After a 36.8% Drop and Gene-Editing Trial Updates